SMTL ID : 7r8n.1

Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

hetero-3-3-3-mer

Ligands

4 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG-NAG.1: 3 residues within 4Å: Chain A: T.108, N.234, T.236 No protein-ligand interaction detected (PLIP) NAG-NAG.2: 2 residues within 4Å: Chain A: N.714, L.919 No protein-ligand interaction detected (PLIP) NAG-NAG.3: 3 residues within 4Å: Chain B: T.108, N.234, T.236 No protein-ligand interaction detected (PLIP) NAG-NAG.4: 1 residues within 4Å: Chain B: N.714 No protein-ligand interaction detected (PLIP)

27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.5: 1 residues within 4Å: Chain A: N.165 Ligand excluded by PLIP NAG.6: 1 residues within 4Å: Chain A: N.282 Ligand excluded by PLIP NAG.7: 2 residues within 4Å: Chain A: N.616, T.618 Ligand excluded by PLIP NAG.8: 1 residues within 4Å: Chain A: N.657 Ligand excluded by PLIP NAG.9: 2 residues within 4Å: Chain A: N.798, Q.801 Ligand excluded by PLIP NAG.10: 3 residues within 4Å: Chain A: N.1095, T.1097, H.1098 Ligand excluded by PLIP NAG.11: 1 residues within 4Å: Chain A: N.1131 Ligand excluded by PLIP NAG.12: 6 residues within 4Å: Chain A: G.339, E.340, N.343 Chain F: W.108 Chain G: T.54, N.55 Ligand excluded by PLIP NAG.13: 2 residues within 4Å: Chain B: Y.28, N.61 Ligand excluded by PLIP NAG.14: 2 residues within 4Å: Chain B: N.164, N.165 Ligand excluded by PLIP NAG.15: 2 residues within 4Å: Chain A: K.558 Chain B: N.282 Ligand excluded by PLIP NAG.16: 2 residues within 4Å: Chain B: N.616, T.618 Ligand excluded by PLIP NAG.17: 1 residues within 4Å: Chain B: N.657 Ligand excluded by PLIP NAG.18: 2 residues within 4Å: Chain B: N.1095, H.1098 Ligand excluded by PLIP NAG.19: 1 residues within 4Å: Chain B: N.1131 Ligand excluded by PLIP NAG.20: 2 residues within 4Å: Chain B: G.339, N.343 Ligand excluded by PLIP NAG.21: 2 residues within 4Å: Chain B: N.798, Q.801 Ligand excluded by PLIP NAG.22: 1 residues within 4Å: Chain C: N.165 Ligand excluded by PLIP NAG.23: 3 residues within 4Å: Chain B: R.466 Chain C: T.108, N.234 Ligand excluded by PLIP NAG.24: 2 residues within 4Å: Chain B: K.558 Chain C: N.282 Ligand excluded by PLIP NAG.25: 3 residues within 4Å: Chain C: N.616, T.618, Q.644 Ligand excluded by PLIP NAG.26: 1 residues within 4Å: Chain C: N.657 Ligand excluded by PLIP NAG.27: 2 residues within 4Å: Chain C: N.714, Q.923 Ligand excluded by PLIP NAG.28: 2 residues within 4Å: Chain C: N.798, Q.801 Ligand excluded by PLIP NAG.29: 2 residues within 4Å: Chain C: N.1095, H.1098 Ligand excluded by PLIP NAG.30: 1 residues within 4Å: Chain C: N.1131 Ligand excluded by PLIP NAG.31: 1 residues within 4Å: Chain C: N.61 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Muecksch, F. et al., Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity (2021)

Release Date

2021-08-04

Peptides

Spike glycoprotein: ABC
C051 Fab Heavy Chain: DFH
C051 Fab Light Chain: EGI

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
E

D
H

F
M

H
O

E
L

G
N

I
P

Spike glycoprotein

C051 Fab Heavy Chain

C051 Fab Light Chain

Related Entries With Identical Sequence